UBE2C is only expressed at low levels in normal tissues, see [1]. However, the expression of UBE2C is high in cancerous tissues of various origins, see [2]. High level of UBE2C expression is prognostic of poor survival in colorectal, thyroid, breast, see [3], ovarian cancer, see [4], lymphoid neoplasm, and in non-small cell lung cancer, see [5]. UBE2C might be a potential marker for tumor response to therapy when down-regulation is detected and the potential of UBE2C as a therapeutic target in cancer should be further explored, see [2].
This APP can be used for quantifying the cytoplasmic expression of UBE2C. A statistically significant correlation to manual scoring, in a study involving 300 patients was found [6].
This APP was developed for, and validated by, Niels Fristrup MD and Dr. Lars Dyrskjøt Andersen, Center for Molecular Clinical Cancer Research Department of Molecular Medicine (MOMA) Aarhus University Hospital.